Widely used biomarkers such as PD-L1 levels, TMB (tumor mutational burden), TIDE, and high microsatellite instability are not always reliable (21), highlighting the need to identify prognostic biomarkers for CRC immunotherapy. Here, CD274 is linked to neoplasm.